title: How do we manage patients treated with antithrombotic therapy in the perioperative interval.
authors.affiliation: Department of Pathology, Texas Heart Institute at St Luke's Episcopal Hospital, Houston, Texas, USA. abracey@msn.com
authors.forename: Arthur W
authors.initials: AW
authors.lastname: Bracey
authors.forename: Meredith A
authors.initials: MA
authors.lastname: Reyes
authors.forename: Alice J
authors.initials: AJ
authors.lastname: Chen
authors.forename: Maryam
authors.initials: M
authors.lastname: Bayat
authors.forename: Paul M
authors.initials: PM
authors.lastname: Allison
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects; D001241:Aspirin / Q000009:adverse effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D000077144:Clopidogrel; D003029:Coagulants / Q000627:therapeutic use; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006488:Hemostasis, Surgical / Q000379:methods; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D019990:Perioperative Care / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019106:Postoperative Hemorrhage / Q000139:chemically induced / Q000517:prevention & control* / Q000628:therapy; D018570:Risk Assessment; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives; D014812:Vitamin K / Q000627:therapeutic use; D014859:Warfarin / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D000991:Antithrombins; D003029:Coagulants; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K; D014859:Warfarin; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin